Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Bioadaptives (BDPT) Gains from Investment Securities (2021 - 2025)

Bioadaptives' Gains from Investment Securities history spans 2 years, with the latest figure at $500000.0 for Q2 2025.

On a quarterly basis, Gains from Investment Securities changed N/A to $500000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $500000.0, a N/A change, with the full-year FY2021 number at $90219.0, changed N/A from a year prior.
Gains from Investment Securities hit $500000.0 in Q2 2025 for Bioadaptives, up from -$94201.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for BDPT hit a ceiling of $500000.0 in Q2 2025 and a floor of -$203303.0 in Q3 2021.